BCAS2 promotes prostate cancer cells proliferation by enhancing AR mRNA transcription and protein stability

British Journal of Cancer

Volumn 112, Issue 2, 2015, Pages 391-402

  Kuo, P C ^a   Huang, C W ^a   Lee, C I ^a   Chang, H W ^a   Hsieh, S W ^a   Chung, Y P ^b   Lee, M S ^a   Huang, C S ^c   Tsao, L P ^a   Tsao, Y P ^d   Chen, S L ^a  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b Taipei Taiwan ROC   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^d MACKAY MEMORIAL HOSPITAL   (Taiwan)

Author keywords

Androgen receptor; BCAS2; HSP90 inhibitor; p53; Prostate cancer

Indexed keywords

ANDROGEN RECEPTOR; BREAST CARCINOMA AMPLIFIED SEQUENCE 2; HEAT SHOCK PROTEIN 90; MESSENGER RNA; PROTEIN P53; REGULATOR PROTEIN; TANESPIMYCIN; UNCLASSIFIED DRUG; BCAS2 PROTEIN, HUMAN; BENZOQUINONE DERIVATIVE; MACROCYCLIC LACTAM; PROTEASOME; TP53 PROTEIN, HUMAN; TUMOR PROTEIN;

ARTICLE; CARBOXY TERMINAL SEQUENCE; CELL GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOSOL; DNA BINDING; FLUORESCENCE MICROSCOPY; GENETIC TRANSCRIPTION; GLEASON SCORE; GROWTH RATE; HALF LIFE TIME; HINGE REGION; HUMAN; HUMAN CELL; IC50; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; IN VITRO STUDY; LNCAP CELL LINE; MALE; MTT ASSAY; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE CANCER; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; PROTEIN STABILITY; REAL TIME POLYMERASE CHAIN REACTION; RECEPTOR UPREGULATION; RNA SPLICING; TRANSIENT TRANSFECTION; WESTERN BLOTTING; ANTAGONISTS AND INHIBITORS; CANCER GRADING; GENE EXPRESSION REGULATION; GENETICS; HEK293 CELL LINE; METABOLISM; PATHOLOGY; PHYSIOLOGY; PROSTATE TUMOR; TUMOR CELL LINE;

BENZOQUINONES; CELL LINE, TUMOR; CELL PROLIFERATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HALF-LIFE; HEK293 CELLS; HSP90 HEAT-SHOCK PROTEINS; HUMANS; INHIBITORY CONCENTRATION 50; LACTAMS, MACROCYCLIC; MALE; NEOPLASM GRADING; NEOPLASM PROTEINS; PROSTATIC NEOPLASMS; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN STABILITY; PROTEOLYSIS; RECEPTORS, ANDROGEN; TRANSCRIPTION, GENETIC; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84921996125     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2014.603     Document Type: Article

References (63)

1. Alimirah F, Panchanathan R, Chen J, Zhang X, Ho SM, Choubey D (2007) Expression of androgen receptor is negatively regulated by p53. Neoplasia 9: 1152-1159.
2. Beck BD, Park SJ, Lee YJ, Roman Y, Hromas RA, Lee SH (2008) Human Pso4 is a metnase (SETMAR)-binding partner that regulates metnase function in DNA repair. J Biol Chem 283: 9023-9030.
3. Biddie SC, Hager GL (2009) Glucocorticoid receptor dynamics and gene regulation. Stress 12: 193-205.
4. Bonnal S, Vigevani L, Valcarcel J (2012) The spliceosome as a target of novel antitumour drugs. Nat Rev Drug Discov 11: 847-859.
5. Centenera MM, Fitzpatrick AK, Tilley WD, Butler LM (2013) Hsp90: still a viable target in prostate cancer. Biochim Biophys Acta 1835: 211-218.
6. Chan SP, Cheng SC (2005) The Prp19-associated complex is required for specifying interactions of U5 and U6 with pre-mRNA during spliceosome activation. J Biol Chem 280: 31190-31199.
7. Chan SP, Kao DI, Tsai WY, Cheng SC (2003) The Prp19p-associated complex in spliceosome activation. Science 302: 279-282.
8. Chanarat S, Sträßer K (2013) Splicing and beyond: the many faces of the Prp19 complex. Biochim Biophys Acta 1833: 2126-2134.
9. Chang SW, Su CH, Chen HH, Huang CW, Tsao LP, Tsao YP, Chen SL (2012) DDB2 is a novel AR interacting protein and mediates AR ubiquitination/degradation. Int J Biochem Cell Biol 44: 1952-1961.
10. Chen PH, Lee CI, Weng YT, Tarn WY, Tsao YP, Kuo PC, Hsu PH, Huang CW, Huang CS, Lee HH, Wu JT, Chen SL (2013) BCAS2 is essential for Drosophila viability and functions in pre-mRNA splicing. RNA 19: 208-218.
11. Chen Y, Sawyers CL, Scher HI (2008) Targeting the androgen receptor pathway in prostate cancer. Curr Opin Pharmacol 8: 440-448.
12. Cheng H, Snoek R, Ghaidi F, Cox ME, Rennie PS (2006) Short hairpin RNA knockdown of the androgen receptor attenuates ligand-independent activation and delays tumor progression. Cancer Res 66: 10613-10620.
13. Gaughan L, Logan IR, Neal DE, Robson CN (2005) Regulation of androgen receptor and histone deacetylase 1 by Mdm2-mediated ubiquitylation. Nucleic Acids Res 33: 13-26.
14. Gray Jr PJ, Stevenson MA, Calderwood SK (2007) Targeting Cdc37 inhibits multiple signaling pathways and induces growth arrest in prostate cancer cells. Cancer Res 67: 11942-11950.
15. Green SM, Mostaghel EA, Nelson PS (2012) Androgen action and metabolism in prostate cancer. Mol Cell Endocrinol 360: 3-13.
16. Grote M, Wolf E, Will CL, Lemm I, Agafonov DE, Schomburg A, Fischle W, Urlaub H, Luhrmann R (2010) Molecular architecture of the human Prp19/CDC5L complex. Mol Cell Biol 30: 2105-2119.
17. Heath EI, Hillman DW, Vaishampayan U, Sheng S, Sarkar F, Harper F, Gaskins M, Pitot HC, Tan W, Ivy SP, Pili R, Carducci MA, Erlichman C, Liu G (2008) A phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with hormone-refractory metastatic prostate cancer. Clin Cancer Res 14: 7940-7946.
18. Hofmann JC, Tegha-Dunghu J, Drager S, Will CL, Luhrmann R, Gruss OJ (2013) The Prp19 complex directly functions in mitotic spindle assembly. PLoS One 8: e74851.
19. Holmes JL, Sharp SY, Hobbs S, Workman P (2008) Silencing of HSP90 cochaperone AHA1 expression decreases client protein activation and increases cellular sensitivity to the HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin. Cancer Res 68: 1188-1197.
20. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA Cancer J Clin 61: 69-90.
21. Jhaveri K, Taldone T, Modi S, Chiosis G (2012) Advances in the clinical development of heat shock protein 90 (Hsp90) inhibitors in cancers. Biochim Biophys Acta 1823: 742-755.
22. Koptyra M, Gupta S, Talati P, Nevalainen MT (2011) Signal transducer and activator of transcription 5a/b: biomarker and therapeutic target in prostate and breast cancer. Int J Biochem Cell Biol 43: 1417-1421.
23. Kuo PC, Tsao YP, Chang HW, Chen PH, Huang CW, Lin ST, Weng YT, Tsai TC, Shieh SY, Chen SL (2009) Breast cancer amplified sequence 2, a novel negative regulator of the p53 tumor suppressor. Cancer Res 69: 8877-8885.
24. Lavery DN, Bevan CL (2011) Androgen receptor signalling in prostate cancer: the functional consequences of acetylation. J Biomed Biotechnol 2011: 862125.
25. Lee DK, Chang C (2003) Endocrine mechanisms of disease: expression and degradation of androgen receptor: mechanism and clinical implication. J Clin Endocrinol Metab 88: 4043-4054.
26. Li H, Ahonen TJ, Alanen K, Xie J, LeBaron MJ, Pretlow TG, Ealley EL, Zhang Y, Nurmi M, Singh B, Martikainen PM, Nevalainen MT (2004) Activation of signal transducer and activator of transcription 5 in human prostate cancer is associated with high histological grade. Cancer Res 64: 4774-4782.
27. Lin HK, Hu YC, Lee DK, Chang C (2004) Regulation of androgen receptor signaling by PTEN (phosphatase and tensin homolog deleted on chromosome 10) tumor suppressor through distinct mechanisms in prostate cancer cells. Mol Endocrinol 18: 2409-2423.
28. Lin HK, Wang L, Hu YC, Altuwaijri S, Chang C (2002) Phosphorylation-dependent ubiquitylation and degradation of androgen receptor by Akt require Mdm2 E3 ligase. EMBO J 21: 4037-4048.
29. Mahajan KN, Mitchell BS (2003) Role of human Pso4 in mammalian DNA repair and association with terminal deoxynucleotidyl transferase. Proc Natl Acad Sci USA 100: 10746-10751.
30. Marivoet S, Van Dijck P, Verhoeven G, Heyns W (1992) Interaction of the 90-kDa heat shock protein with native and in vitro translated androgen receptor and receptor fragments. Mol Cell Endocrinol 88: 165-174.
31. McNally JG, Muller WG, Walker D, Wolford R, Hager GL (2000) The glucocorticoid receptor: rapid exchange with regulatory sites in living cells. Science 287: 1262-1265.
32. Modi S, Stopeck A, Linden H, Solit D, Chandarlapaty S, Rosen N, D'Andrea G, Dickler M, Moynahan ME, Sugarman S, Ma W, Patil S, Norton L, Hannah AL, Hudis C (2011) HSP90 inhibition is effective in breast cancer: a phase II trial of tanespimycin (17-AAG) plus trastuzumab in patients with HER2-positive metastatic breast cancer progressing on trastuzumab. Clin Cancer Res 17: 5132-5139.
33. Nacusi LP, Tindall DJ (2011) Targeting 5alpha-reductase for prostate cancer prevention and treatment. Nat Rev Urol 8: 378-384.
34. Ohtake F, Fujii-Kuriyama Y, Kawajiri K, Kato S (2011) Cross-talk of dioxin and estrogen receptor signals through the ubiquitin system. J Steroid Biochem Mol Biol 127: 102-107.
35. Pacey S, Gore M, Chao D, Banerji U, Larkin J, Sarker S, Owen K, Asad Y, Raynaud F, Walton M, Judson I, Workman P, Eisen T (2012) A Phase II trial of 17-allylamino, 17-demethoxygeldanamycin (17-AAG, tanespimycin) in patients with metastatic melanoma. Invest New Drugs 30: 341-349.
36. Paduano F, Villa R, Pennati M, Folini M, Binda M, Daidone MG, Zaffaroni N (2006) Silencing of survivin gene by small interfering RNAs produces supra-additive growth suppression in combination with 17-allylamino-17-demethoxygeldanamycin in human prostate cancer cells. Mol Cancer Ther 5: 179-186.
37. Porter JR, Fritz CC, Depew KM (2010) Discovery and development of Hsp90 inhibitors: a promising pathway for cancer therapy. Curr Opin Chem Biol 14: 412-420.
38. Pozzobon A, Schneider L, Brum IS (2012) Androgen-modulated p21 and p53 gene expression in human non-transformed epithelial prostatic cells in primary cultures. Int J Mol Med 30: 967-973.
39. Pratt WB, Morishima Y, Murphy M, Harrell M (2006) Chaperoning of glucocorticoid receptors. Handb Exp Pharmacol 172: 111-138.
40. Qi C, Zhu YT, Chang J, Yeldandi AV, Rao MS, Zhu YJ (2005) Potentiation of estrogen receptor transcriptional activity by breast cancer amplified sequence 2. Biochem Biophys Res Commun 328: 393-398.
41. Rahman M, Miyamoto H, Chang C (2004) Androgen receptor coregulators in prostate cancer: mechanisms and clinical implications. Clin Cancer Res 10: 2208-2219.
42. Saraon P, Jarvi K, Diamandis EP (2011) Molecular alterations during progression of prostate cancer to androgen independence. Clin Chem 57: 1366-1375.
43. Sengupta D, Bhargava DK, Dixit A, Sahoo BS, Biswas S, Biswas G, Mishra SK (2014) ERRbeta signalling through FST and BCAS2 inhibits cellular proliferation in breast cancer cells. Br J Cancer 110: 2144-2158.
44. Shafi AA, Yen AE, Weigel NL (2013) Androgen receptors in hormone-dependent and castration-resistant prostate cancer. Pharmacol Ther 140: 223-238.
45. Shatkina L, Mink S, Rogatsch H, Klocker H, Langer G, Nestl A, Cato AC (2003) The cochaperone Bag-1L enhances androgen receptor action via interaction with the NH2-terminal region of the receptor. Mol Cell Biol 23: 7189-7197.
46. Shenk JL, Fisher CJ, Chen SY, Zhou XF, Tillman K, Shemshedini L (2001) p53 represses androgen-induced transactivation of prostate-specific antigen by disrupting hAR amino- to carboxyl-terminal interaction. J Biol Chem 276: 38472-38479.
47. Smith JR, Clarke PA, de Billy E, Workman P (2009) Silencing the cochaperone CDC37 destabilizes kinase clients and sensitizes cancer cells to HSP90 inhibitors. Oncogene 28: 157-169.
48. Solit DB, Osman I, Polsky D, Panageas KS, Daud A, Goydos JS, Teitcher J, Wolchok JD, Germino FJ, Krown SE, Coit D, Rosen N, Chapman PB (2008) Phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with metastatic melanoma. Clin Cancer Res 14: 8302-8307.
49. Solit DB, Rosen N (2006) Hsp90: a novel target for cancer therapy. Curr Top Med Chem 6: 1205-1214.
50. Solit DB, Scher HI, Rosen N (2003) Hsp90 as a therapeutic target in prostate cancer. Semin Oncol 30: 709-716.
51. Solit DB, Zheng FF, Drobnjak M, Munster PN, Higgins B, Verbel D, Heller G, Tong W, Cordon-Cardo C, Agus DB, Scher HI, Rosen N (2002) 17-Allylamino-17-demethoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts. Clin Cancer Res 8: 986-993.
52. Tan SH, Dagvadorj A, Shen F, Gu L, Liao Z, Abdulghani J, Zhang Y, Gelmann EP, Zellweger T, Culig Z, Visakorpi T, Bubendorf L, Kirken RA, Karras J, Nevalainen MT (2008) Transcription factor Stat5 synergizes with androgen receptor in prostate cancer cells. Cancer Res 68: 236-248.
53. Taplin ME (2007) Drug insight: role of the androgen receptor in the development and progression of prostate cancer. Nat Clin Pract Oncol 4: 236-244.
54. Taplin ME (2008) Androgen receptor: role and novel therapeutic prospects in prostate cancer. Expert Rev Anticancer Ther 8: 1495-1508.
55. Thomas C, Zoubeidi A, Kuruma H, Fazli L, Lamoureux F, Beraldi E, Monia BP, MacLeod AR, Thuroff JW, Gleave ME (2011) Transcription factor Stat5 knockdown enhances androgen receptor degradation and delays castration-resistant prostate cancer progression in vivo. Mol Cancer Ther 10: 347-359.
56. Tsai TC, Lee YL, Hsiao WC, Tsao YP, Chen SL (2005) NRIP, a novel nuclear receptor interaction protein, enhances the transcriptional activity of nuclear receptors. J Biol Chem 280: 20000-20009.
57. Usmani SZ, Bona R, Li Z (2009) 17 AAG for HSP90 inhibition in cancer-from bench to bedside. Curr Mol Med 9: 654-664.
58. Vanaja DK, Mitchell SH, Toft DO, Young CY (2002) Effect of geldanamycin on androgen receptor function and stability. Cell Stress Chaperones 7: 55-64.
59. Wan L, Huang J (2014) The PSO4 protein complex associates with replication protein A (RPA) and modulates the activation of ataxia telangiectasia-mutated and Rad3-related (ATR). J Biol Chem 289: 6619-6626.
60. Wen Y, Hu MC, Makino K, Spohn B, Bartholomeusz G, Yan DH, Hung MC (2000) HER-2/neu promotes androgen-independent survival and growth of prostate cancer cells through the Akt pathway. Cancer Res 60: 6841-6845.
61. Worsham MJ, Pals G, Schouten JP, Miller F, Tiwari N, van Spaendonk R, Wolman SR (2006) High-resolution mapping of molecular events associated with immortalization, transformation, and progression to breast cancer in the MCF10 model. Breast Cancer Res Treat 96: 177-186.
62. Zhang N, Kaur R, Akhter S, Legerski RJ (2009) Cdc5L interacts with ATR and is required for the S-phase cell-cycle checkpoint. EMBO Rep 10: 1029-1035.
63. Zhou ZX, He B, Hall SH, Wilson EM, French FS (2002) Domain interactions between coregulator ARA(70) and the androgen receptor (AR). Mol Endocrinol 16: 287-300.